SCHEDULE: TCG Crossover Funds Disclose 6.2% Stake in Tectonic Therapeutic

TCG Crossover Funds and Chen Yu have disclosed a combined 6.2% beneficial ownership stake in Tectonic Therapeutic, Inc. common stock.

Summary

• TCG Crossover GP II, LLC, TCG Crossover Fund II, L.P., TCG Crossover GP III, LLC, TCG Crossover Fund III, L.P., and Chen Yu (collectively, the Reporting Persons) have filed a Schedule 13G.
• Chen Yu, as the sole managing member of TCG Crossover GP II and TCG Crossover GP III, beneficially owns an aggregate of 1,169,760 shares of Tectonic Therapeutic, Inc. common stock.
• This aggregate ownership represents 6.2% of the issuer's outstanding Common Stock.
• TCG Crossover Fund II, L.P. and TCG Crossover GP II, LLC each beneficially own 584,882 shares, representing 3.1% of the class.
• TCG Crossover Fund III, L.P. and TCG Crossover GP III, LLC each beneficially own 584,878 shares, representing 3.1% of the class.
• The percentage ownership is based on 18,776,626 shares of Common Stock outstanding as of February 16, 2026, as reported by Tectonic Therapeutic, Inc. in its Annual Report on Form 10-K filed on February 26, 2026.
• The securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as a reputable investment firm has taken a significant passive stake, which can be interpreted as a vote of confidence in Tectonic Therapeutic's long-term potential.

Positives

• A significant investment firm, TCG Crossover, has taken a notable stake in Tectonic Therapeutic, potentially signaling confidence in the company's long-term prospects.

Future Outlook

Not applicable, as this filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures by passive investors who acquire more than 5% of a company's stock. The disclosure of TCG Crossover's stake indicates a significant institutional investor's belief in Tectonic Therapeutic, which operates in the biotechnology sector. Such filings can sometimes draw attention to a company, especially if the investor is well-regarded in the industry.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake may increase investor confidence and potentially attract further institutional interest.
• Company Management: Awareness of a new significant shareholder may influence strategic considerations, though the filing explicitly states the stake is passive.

Key Dates

Recommendation

A Schedule 13G filing indicates a passive investment by a significant entity, TCG Crossover, in Tectonic Therapeutic. While this can be seen as a positive signal of institutional confidence, the filing itself does not provide new operational or financial data to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and monitor future company performance and additional disclosures for more actionable insights, as this filing primarily confirms a change in ownership structure rather than a change in company fundamentals.

Keywords

Tectonic Therapeutic, TCG Crossover, Chen Yu, Beneficial Ownership, Schedule 13G, Common Stock, Investment Firm, Biotechnology, Healthcare